The long and winding road of non steroidal antinflammatory drugs andparacetamol in cancer pain management: A critical review

Antonino Giarratano, Sebastiano Mercadante, Antonino Giarratano

Risultato della ricerca: Article

25 Citazioni (Scopus)

Abstract

The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous reviewperformed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, whichoften does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases werecollected from January 2001 to December 2011. A free-text search method was used including the following words and their combination:“Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered.Thirteen reports fulfitted inclusion criteria in this systematic review. Randomized trials have been performed by using different modalitiesof intervention. Single drugs added on opioid therapy or during opioid substitution with opioids as rescue drugs through a patient controlledanalgesia, were compared with placebo or between them. Five studies regarded paracetamol. Other four studies assessed the efficacy dipyrone,ketorolac, dexketoprofen, and subcutaneous ketoprofen in cancer pain management, mainly on top of an opioid regimen. The role of paracetamoland NSAIDs in the management of cancer pain still remains controversial. The papers published in this last decade were unable to answerthe main questions. There is no proof that they should be used to start the treatment and how long they should be administered when opioidtreatment is added on top. While paracetamol seems to be devoid of any benefit, particularly if given at usual clinical doses which shouldbe less than 4 g/day, ketorolac seems to provide an additive analgesic effect even in patients receiving different doses of opioids. The mainindication from the analysis of these data is that NSAIDs could be given in patients receiving opioids, evaluating their benefit and weight onopioid therapy in individual patients who have a favorable response to justify a prolonged use.
Lingua originaleEnglish
Numero di pagine0
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume1
Stato di pubblicazionePublished - 2013

Fingerprint

Pain Management
Opioid Analgesics
Acetaminophen
Non-Steroidal Anti-Inflammatory Agents
Pharmaceutical Preparations
Ketorolac
Drug Repositioning
Dipyrone
Ketoprofen
Analgesics
Cancer Pain
Anti-Inflammatory Agents
Therapeutics
Randomized Controlled Trials
Placebos
Databases
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

@article{0d33cd6b2020486d84625f15b3dc1d9c,
title = "The long and winding road of non steroidal antinflammatory drugs andparacetamol in cancer pain management: A critical review",
abstract = "The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous reviewperformed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, whichoften does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases werecollected from January 2001 to December 2011. A free-text search method was used including the following words and their combination:“Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered.Thirteen reports fulfitted inclusion criteria in this systematic review. Randomized trials have been performed by using different modalitiesof intervention. Single drugs added on opioid therapy or during opioid substitution with opioids as rescue drugs through a patient controlledanalgesia, were compared with placebo or between them. Five studies regarded paracetamol. Other four studies assessed the efficacy dipyrone,ketorolac, dexketoprofen, and subcutaneous ketoprofen in cancer pain management, mainly on top of an opioid regimen. The role of paracetamoland NSAIDs in the management of cancer pain still remains controversial. The papers published in this last decade were unable to answerthe main questions. There is no proof that they should be used to start the treatment and how long they should be administered when opioidtreatment is added on top. While paracetamol seems to be devoid of any benefit, particularly if given at usual clinical doses which shouldbe less than 4 g/day, ketorolac seems to provide an additive analgesic effect even in patients receiving different doses of opioids. The mainindication from the analysis of these data is that NSAIDs could be given in patients receiving opioids, evaluating their benefit and weight onopioid therapy in individual patients who have a favorable response to justify a prolonged use.",
author = "Antonino Giarratano and Sebastiano Mercadante and Antonino Giarratano",
year = "2013",
language = "English",
volume = "1",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The long and winding road of non steroidal antinflammatory drugs andparacetamol in cancer pain management: A critical review

AU - Giarratano, Antonino

AU - Mercadante, Sebastiano

AU - Giarratano, Antonino

PY - 2013

Y1 - 2013

N2 - The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous reviewperformed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, whichoften does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases werecollected from January 2001 to December 2011. A free-text search method was used including the following words and their combination:“Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered.Thirteen reports fulfitted inclusion criteria in this systematic review. Randomized trials have been performed by using different modalitiesof intervention. Single drugs added on opioid therapy or during opioid substitution with opioids as rescue drugs through a patient controlledanalgesia, were compared with placebo or between them. Five studies regarded paracetamol. Other four studies assessed the efficacy dipyrone,ketorolac, dexketoprofen, and subcutaneous ketoprofen in cancer pain management, mainly on top of an opioid regimen. The role of paracetamoland NSAIDs in the management of cancer pain still remains controversial. The papers published in this last decade were unable to answerthe main questions. There is no proof that they should be used to start the treatment and how long they should be administered when opioidtreatment is added on top. While paracetamol seems to be devoid of any benefit, particularly if given at usual clinical doses which shouldbe less than 4 g/day, ketorolac seems to provide an additive analgesic effect even in patients receiving different doses of opioids. The mainindication from the analysis of these data is that NSAIDs could be given in patients receiving opioids, evaluating their benefit and weight onopioid therapy in individual patients who have a favorable response to justify a prolonged use.

AB - The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous reviewperformed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, whichoften does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases werecollected from January 2001 to December 2011. A free-text search method was used including the following words and their combination:“Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered.Thirteen reports fulfitted inclusion criteria in this systematic review. Randomized trials have been performed by using different modalitiesof intervention. Single drugs added on opioid therapy or during opioid substitution with opioids as rescue drugs through a patient controlledanalgesia, were compared with placebo or between them. Five studies regarded paracetamol. Other four studies assessed the efficacy dipyrone,ketorolac, dexketoprofen, and subcutaneous ketoprofen in cancer pain management, mainly on top of an opioid regimen. The role of paracetamoland NSAIDs in the management of cancer pain still remains controversial. The papers published in this last decade were unable to answerthe main questions. There is no proof that they should be used to start the treatment and how long they should be administered when opioidtreatment is added on top. While paracetamol seems to be devoid of any benefit, particularly if given at usual clinical doses which shouldbe less than 4 g/day, ketorolac seems to provide an additive analgesic effect even in patients receiving different doses of opioids. The mainindication from the analysis of these data is that NSAIDs could be given in patients receiving opioids, evaluating their benefit and weight onopioid therapy in individual patients who have a favorable response to justify a prolonged use.

UR - http://hdl.handle.net/10447/73909

M3 - Article

VL - 1

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -